SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Biotech/Tech Stocks with alot of Cash/Equity -- Ignore unavailable to you. Want to Upgrade?


To: John Liu who wrote (1)5/11/2000 10:43:00 AM
From: david james  Read Replies (1) | Respond to of 18
 
John, with respect to Cell Genesys (CEGE),
your numbers aren't quite right.

$250 mill in cash.
4.852 mill shares of ABGX which right now is at 92
4.852*92 = $446 mill

Cash and equity = $696 mill. = $19.3/share

They are also like to be profitable the rest of the year based primarily on the licensing of their technology and payments by Japanese Tobacco. JT is paying $45 mill for the Asian rights to their lung and prostate cancer vaccines.